FibroGen's lung disease treatment fails in late-stage trial (updated)

Kyntra Bio

26/06/2023 12:22

(Adds details on trial in paragraph 2, background on disease in
paragraph 3)
       June 26 (Reuters) - FibroGen  FGEN.O  said on Monday its
experimental drug, pamrevlumab, for treating lung disease
idiopathic pulmonary fibrosis (IPF) did not meet its main goal
in a late-stage study. 
    Based on the results from the study, the company said it
would discontinue a second late-stage trial on the drug, adding
that it plans to implement a "significant cost reduction effort"
in the U.S. to extend its cash runway into 2026.
    IPF is a chronic lung disease, which is characterized by a
progressive and irreversible decline in lung function. 
    
    
    

 (Reporting by Raghav Mahobe in Bengaluru; Editing by Shinjini
Ganguli)
 ((Raghav.Mahobe@thomsonreuters.com;))